Key Takeaways
- Record quarter, margin squeeze: Revenue and absolute EBITDA hit all-time highs with 18% YoY growth, but EBITDA margin slipped to 11.3% as a March raw material spike of 25-30% compressed gross margins before April pass-through could take effect.
- Core B2B is the profit engine: Excluding the loss-making institutional and B2C businesses, core B2B operations delivered a 14% EBITDA margin for the full year, revealing the underlying earnings power beneath the consolidated 11.9%.
- CAPEX rephasing signals capital discipline: Management cut planned FY27 CAPEX to ₹50-75 crore from an earlier ₹192 crore, explicitly prioritizing cash flow, ROCE and letting current capacity generate returns before spending further.
- Debt-free ambition set: The company targets becoming debt-free within 18 months, funded by non-core asset sales, product-line trimming and operating cash flow.
- What to watch next quarter: Whether the April raw material pass-through restores gross margins, the pace of non-core asset sales, and any concrete progress on exiting or restructuring the B2C and institutional businesses.
Topline & Segment Performance
- Broad-based growth across all three segments: HPPC grew 18%, Textiles 20%, and AHN 14% in Q4, with exports up 11% for the full year on deeper customer engagement and expansion into Latin America, Europe, Southeast Asia and Africa.
- Domestic demand was patchy: Domestic conditions remained relatively soft during certain periods of the year, making export momentum the more reliable growth driver.
- Subsidiary contribution improved: Higher utilization of the Unitop 15,000-ton capacity drove subsidiary growth in Q4, with utilization described as "little more, better than Q3" and still ramping.
- Institutional and B2C remain a drag: Both businesses continued operating in a challenging environment with muted growth, though losses moderated through the second half on improved product mix, operational efficiency and cost discipline.
- FY27 growth target set at 15%: Management expects minimum similar growth to FY26, with pharma, agro, oil and gas and new pharma segments as the named drivers; acceleration depends on global conditions improving.
Margin Dynamics & Raw Material Pass-Through
- The March raw material spike was the quarter's margin story: Raw material prices rose 25-30% in March, forcing the company to buy at elevated prices to honor customer orders, which compressed gross margins before the pass-through cycle could begin.
- Pass-through achieved from April 1: Management confirmed that from April onwards, all high-purchase raw material costs have been passed through to customers, with acceptance attributed to visible global geopolitical conditions. Some resistance surfaced in textiles, met by controlling supplies to enforce profitable margins.
- Sales mix also weighed on margins: Beyond raw materials, the product mix shift within the quarter contributed to the gross margin decline, alongside elevated expenses from capacity expansion, new business development and capability building.
- FY27 margin guided flat at 12-13%: Management expects EBITDA margin to remain at current levels, with improvement levers from higher-margin segments like pharma expected to materialize only in the second half of FY27.
- Employee cost growth to normalize: Employee costs rose significantly in FY26 as an investment for expansion plans; management stated this growth rate will not continue at similar levels.
Chari: "Unlike other industries, our dependence on Middle East is not as much as the other countries. Of course prices globally have risen... from this month onwards, we have been able to pass through all our high purchase raw materials into adding margins and getting the final prices. The customers are accepting because everybody can see the global geopolitical situation."
CAPEX, Capacity & Capital Allocation
- CAPEX rephased sharply downward: Earlier plans for ₹192 crore of spend across Rossari, Unitop and Tristar have been internally rephased to ₹50-75 crore for the current year, driven by evolving business requirements and market conditions.
- The logic is returns-first, not growth-at-any-cost: Management wants current capacity to generate the returns originally earmarked before committing further capital, explicitly linking the decision to cash flow management and ROCE optimization.
- Ethoxylation utilization is effectively maxed out: The Dahej plant runs at 90-100% utilization, 24/7, 365 days a year with no downtime except for expansion-related stops, taking total installed capacity to 66,000 metric tons.
- New capacities coming online: A Thailand blending unit was commissioned in late March, a premix plant originally slated for Q1 FY27 has already been commissioned, and one pharma product CAPEX will come up sometime this year.
- Reliance EO expansion matters for input supply: New ethylene oxide capacities at Reliance are expected by Q3 FY27, which should ease domestic supply; currently all EO is sourced domestically with no Middle East imports.
Sablok: "It is just an optimization of our spend in terms of cash flow management and the ratios that we are looking, ROCES. We would like at least the current capacity to generate some of the returns that we have earmarked, and then probably go ahead and spend on these remaining CAPEX plans."
Portfolio Restructuring & Non-Core Exits
- B2C business is loss-making and under review: Management is evaluating restructuring of consumer-focused businesses and may cash out if appropriate value can be obtained, though no timeline or value range was offered.
- Institutional business targeting breakeven in FY27: After a muted FY26 with expanding losses, management expects the institutional business to reach breakeven or profitability this year.
- Non-core asset sales have begun: The sale of Mumbai office space generated ₹19 crore of net income in Q4, described as the first step in liquidating non-core assets; more office spaces and other unutilized assets across India are slated for sale during the current year.
- Product profile trimming planned: Management intends to trim the product profile and business segments, with some implementations planned this year, focusing instead on value-added products with higher margins in food, personal care, pharma, cosmetics and animal health and nutrition.
- Debt-free target within 18 months: The plan is to bring down debt significantly over this year and the next, funded by asset sales, product-line rationalization and operating cash flow.
- Divestment timeline is deliberately open-ended: Management declined to hazard any number or timeline for non-core business exits, stating only that the plan is to happen in 2027 but could take more than a year or two, with the priority being exit at good value.
Sablok: "The target is to actually get debt free in the next 18 months, but the time will tell. Currently, the plan is to keep bringing down our debt over the next 18 months."
Geographic & End-Market Expansion
- Thailand plant to contribute from Q2 FY27: The newly commissioned blending unit will start with textile chemicals, then expand into AHN and possibly home and personal care, with meaningful contribution expected from Q2 onwards.
- Export textiles expected to outpace domestic: Management sees export growth in textiles outperforming domestic through Bangladesh, Southeast Asia, Thailand, Turkey and Brazil.
- North America in sight for personal care and agro: The company is looking at the North American market for these two segments, while already maintaining a strong agro presence in Latin America that it aims to build further.
- Saudi Arabia initiative still alive: Despite recent geopolitical developments, management remains confident of expansion plans and describes the initiative as an important strategic step, though no timeline was provided.
- Value-added shift is the strategic pivot: The company is deliberately focusing on higher-margin segments while cutting low-margin products, with the ramp-up in pharma, food, personal care and cosmetics expected to play out over the next 2-3 years.
Management Posture & Unanswered Questions
- Segment margin disclosure denied: When asked for segment-wise EBITDA margins across HPPC, textiles and AHN, management declined, offering only a qualitative sense that all three stay near company-level margins with possible 1-2% variation.
- Share buyback ruled out: Despite the stock trading at what an analyst described as a historical low of less than 10x EBITDA, management stated plainly that no buyback is on the cards.
- Value-added sales metric rejected: A request for a metric to track value-added sales growth from next quarter was declined, with management saying they would "think about" how to do it but could not share such detail.
- Divestment quantification avoided: Management declined to provide any rupee value range or timeline for the divestment of non-core assets or consumer businesses, calling any number a hazard.
- Promoter exit rumours dismissed: In response to market speculation about promoter stake sales, management stated there is "nothing of such at all" and that the team is focused on growth.
Chari: "I think there is nothing of such at all. We are all sitting, working and focusing on growth. Market rumours will come and go. There is nothing on the plan at this moment."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Minimum 15% growth, driven by pharma, agro, oil and gas and new pharma segments | FY27 |
| EBITDA margin | Remain at 12-13% on a consolidated basis; improvement levers from pharma expected in H2 | FY27 |
| CAPEX spend | ₹50-75 crore, down from earlier ₹192 crore plan | FY27 |
| Debt reduction | Become debt-free, funded by asset sales, product trimming and operating cash flow | Within 18 months |
| Institutional business | Reach breakeven or profitability | FY27 |
| Employee cost growth | Growth rate will not continue at FY26 levels | FY27 |
| Thailand plant contribution | Meaningful revenue contribution starting with textile, then AHN and HPPC | From Q2 FY27 |
| Pharma product CAPEX | One pharma product CAPEX to come up | Sometime in FY27 |
| Non-core asset sales | More office spaces and unutilized assets to be liquidated | During FY27 |
| B2C business restructuring | Evaluate restructuring or exit at good value; plan is to happen in 2027 | 2027 or longer |
| High-margin segment ramp-up | Pharma, food, personal care, cosmetics ramp-up to support margin improvement | Next 2-3 years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹684.9 cr, +18% YoY, highest-ever quarterly revenue |
| EBITDA | ₹77.3 cr, +11% YoY, highest-ever quarterly absolute EBITDA |
| EBITDA margin | 11.3%, vs 12% in Q4 FY25 |
| FY26 full-year revenue | ₹2,396.4 cr, +15% YoY |
| FY26 full-year EBITDA | ₹286 cr, +8% YoY |
| FY26 full-year EBITDA margin | 11.9%, vs 12.7% in FY25 |
| Core B2B EBITDA margin (FY26) | 14%, excluding institutional and B2C businesses |
| HPPC segment growth | 18% YoY |
| Textiles segment growth | 20% YoY |
| AHN segment growth | 14% YoY |
| Exports growth (FY26) | 11% YoY |
| Installed ethoxylation capacity | 66,000 MT per annum at Dahej |
| Ethoxylation utilization | 90% to 100%, running 24/7, 365 days a year |
| FY27 revenue growth guidance | At least 15% YoY, similar to FY26 |
| FY27 EBITDA margin guidance | 12% to 13% |
| FY27 CAPEX plan | ₹50 cr to ₹75 cr |
| Long-term debt | ~₹200 cr, balance is short-term working capital borrowings |
| B2C business revenue (FY26) | ~₹250 cr to ₹260 cr, balance of total revenue is B2B |
| Top 10 customer concentration | 12% to 13% of revenue, no single customer more than 2% |
| Net income from sale of Mumbai office space | ₹19 cr |
| Raw material price increases in March | 25% to 30% on some raw materials |
| Thailand plant peak revenue potential | ₹50 cr to ₹75 cr |
| 6-year sales CAGR | 25% |
| 6-year profit CAGR | 18% |